JP Morgan Maintains Overweight on Medline, Lowers Price Target to $46

Benzinga Newsdesk www.benzinga.com Negative 92.3%

Neg 92.3% Neu 0% Pos 0%

JP Morgan analyst Lisa Gill maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $53 to $46.